IP CHALLENGES AND Opportunities for Indian Pharma GENERICS

© www.descienceinfoware.com
IP CHALLENGES
AND
OPPORTUNITIES
FOR INDIAN PHARMA GENERICS
sandeepm@scienceinfoware.com
+91 8953745897
Questel’s Partner in India
Starting at 3:00 PM IST
May 6th 2016

AGENDA
Quickly Identify key Expiring Patents for Pharmaceutical Industry
Optimize Risk & perform in-depth FTO analysis
Locate unexplored market, Fine-tune R&D and Maximize ROI
Track Competition trough Orbit IP Business Intelligence
Find Hidden Patent Information
Analyze Non-Patent Literature (INTELLIXIR)

Finding Patents in ROW market
Locate IP wherein No FullText is present
Analyze ‘Expiring Patents’ for Pharma Industry
Finding & Analyzing Supplementary Protection Certificates, legal Status, litigation and licensing information
Precisely locate related patents to catch abandoned, withdrawn or limiting publications
Technology Scouting of big set of results, locate valuable IP to design-around
Analyze in single report Patent, Non-Patent & Clinical Trials
CHALLENGES FOR PHARMA INDUSTRY IN PATENT INFORMATION

Objective is to analysis of antidiabetic sector
Manner:-
Concepts are taken to derive search, can be further limited to technology domain or specific classifications
Limited to Alive patent Families
Used quick list to create custom Graphs
Further filtered using value added information e.g. Litigation, Special Protection certificates, Licensing Information,
Family Size, Regulatory listing as medicinal patent.
Browsing Technology and creating environment for value added drafting of Patent Application
QUICKLY IDENTIFY KEY EXPIRING PATENTS

Concepts used for finding antidiabetic patent portfolios
( (ANTIDIABETIC AGENT OR ANTIDIABETIC OR ANTIDIABETIC DRUG OR ANTIHYPERTENSIVE AGENT OR PIOGLITAZONE OR HYPOGLYCEMIC AGENT OR
CHOLESTEROL ABSORPTION INHIBITOR OR SULFONYLUREA OR ANTIARRHYTHMIC AGENT OR APPETITE SUPPRESSANT OR REPAGLINIDE OR
ACARBOSE OR GLUCAGON ANTAGONIST OR GLIBENCLAMIDE OR TOLBUTAMIDE OR PPAR GAMMA AGONIST OR PPAR OR THIAZOLIDINEDIONE OR
DIABETES MELLITUS OR INSULIN OR GLUCOSE OR PHARMACEUTICAL COMPOSITION OR BLOOD GLUCOSE OR DRUG OR DIABETIC PATIENT OR
OBESITY OR ADMINISTRATION OR DISEASE OR INSULIN SECRETION OR INSULIN SENSITIVITY)/KEYW/TI/AB/IW AND (INSULIN RESISTANCE OR
METABOLIC SYNDROME OR OBESITY OR INSULIN SENSITIVITY OR DYSLIPIDEMIA OR HYPERINSULINEMIA OR HYPERTRIGLYCERIDEMIA OR INSULIN
OR GLUCOSE INTOLERANCE OR DIABETES MELLITUS OR GLUCOSE TOLERANCE OR INSULIN SECRETION OR HYPERLIPIDEMIA)/KEYW/TI/AB/IW )
Supplementary Protection Certificate
Legal Status
Expiry (Year)
Limit patents with
Opposition
Licensing
Litigation
IDENTIFY RELEVANT PATENTS

Search History
 Advanced search for expiry year
 Create Quick list by Years
 Status filter or Dead/Alive
 Licensing and Medicinal patents
 Legal Status based Screening
SELECT & MANAGE PATENTS OF INTEREST

Quickly create Top
Technology Players,
Assignee, Competitors
Combine assignee name
variation in one click –
suggested groupings
One can combine Merger
and Acquisition using our
Corporate Tree in one Go.
IDENTIFY KEY COMPETITOR PATENTS

Find Technology exhaustion
and Free market
Interactive Map to locate and
pinpoint IP families
Visualize Plans and Main
Markets
QUICKLY MAP KEY MARKETS

QUICKLY MAP ACTIVITY IN DESIRED MARKET
Country interactive Map based on query

ANALYZING THE DESIRED MARKET LEGAL ENFORCEMENT

Locate potential IP with SPC & not filed/protected in
India and ready to use
FTO in countries along side of Potential Market
LOCATE POTENTIAL IP WITH SPC & NOT FILED/PROTECTED IN INDIA

Forecast and Plan Product mix
way ahead of key player
patents expiry
Map IP based on predefined
Expiry quick-list or work-file
Can be used to create custom
charts with specific needs. e.g.
IP claiming combinations
ANT-DIABETIC : KEY PLAYERS WITH PATENT EXPIRY IN NEXT 5YRS

Mining IP based on concepts – could be filtered based on expiry, assignee, legal status, litigation
ANT-DIABETIC : KEY CONCEPTS WITH PATENT EXPIRY IN NEXT 5YRS

Drill Down of the specific
information
BUILD STRATEGIES FOR RESEARCH & DEVELOPMENT

European IP having SPC but not having
Indian Patent applications Expiring in next
5 years
EUROPEAN PATENTS NOT HAVING INDIAN FAMILY

Expiring patents in 2016
years
=
Potential Technologies to
Develop
Alive patents
=
Technologies to Design
Around, Innovante
Analyze alive and Dead Patents to strategies
Generic Technology Niche
IDENTIFY WHITE SPACES WITH EXPIRY

Cut through thousands of patents to
identify a small number of key
technologies which are gaining
traction.
Rank patents based on the use of
specific scouting potential metrics
Transform them into acquisition
opportunities.
SCOUT IP FOR PHARMA GENERICS

FIND PATENTS FOR IN DEPTH ANALYSIS AND RANKING

COMBINE & CLEAN DATA SETS

TAKE HELP FROM VALUATION MATRICES

Where you are going
Who you’re up against
How well prepared you are
Before a product launch
Before investing in an RD project
Milestone reviews for an RD project
Before acquiring a company or product line
When ever you request a freedom to operate search
To Understand When to Do?
LEGAL RISK ASSESSMENT

LEGAL RISK ASSESSMENT

LEGAL RISK ASSESSMENT - REPORTS

Industry Leader Generic Manufacturer
VALUE IP FOR GENERICS

SWOTPHARMA
BUSINESS IDEA
LOCATION
INVESTMENT
OPPORTUNITIES
THREATS
SWOT
STRENGTHS WEAKNESSES
OPPORTUNITIES THREATS
TECHNOLOGY
BUSINESS CASE ASSESSMENT

Search for mechanism
in the full text of
worldwide patents
database (the three
keywords have to be
in the same sentence)
(TYROSINE S KINASE S INHIB+)/TX AND ((+PYRIMID+ OR “1”_”3”_DIAZIN+) AND (+BENZAMID+ OR
+BENZOYLAMID+ OR (+AMID+ S (+BENZ+ OR PHENYL+))))/BI/OBJ/CLMS OR (IMATINIB OR GLIVEC OR
GLEEVEC OR CGP_57148? OR STI571)/BI/OBJ/ICLM
TYROSINE S
KINASE S INHIB+
AND
Search for main
chemical function
(and its synonyms) of
the compound in title,
abstract and claims of
worldwide patent
database
+PYRIMID+ OR
“1”_”3”_diazine
AND
Search for the
modifying chemical
group (and its
synonyms) in title,
abstract and claims of
worldwide patent
database
(+BENZAMID+ OR
+BENZOYLAMID+
OR (+AMID+ S
(+BENZ+ OR
PHENYL+))))
OR
Search for the name of
the compound in title,
abstract and
independant claims of
worldwide patent
database
IMATINIB OR
GLIVEC OR
GLEEVEC OR
CGP_57148? OR
STI571
3471 patent families
CHEMICAL MOLECULE SEARCH

On one glance Patent
seems to be only member
and No National Phase.
FIND HIDDEN IP INFORMATION

Use More like this tool to get
Patents closely associated

OPTIMIZE PATENT SEARCH

LITIGATION DOCUMENTS

LICENSING DOCUMENTS

Examples included in the Description of US Documents /DESX
("3" W +hydroxyl+ W "2" W pyridin_amin? )/DESX
Number of Unique Filings in a Family /NPN
NPN=1 NPN>=5 NPN=10:15
US Reassignments REAS=YES
Licensing documents EG/ACT=LID
Supplementary Protection Certificate EG/ACT=SPC
Litigation filed in US District courts, from 1980 CID=YES
Medicinal Patent TELMISARTAN/MED
COMMAND LINE USE

INTEGRATING SEARCH

ANALYZE NON-PATENT & PATENT LITERATURE TOGETHER

Many of them does
not even require any
further optimization
HIGH-END INTERACTIVE ANALYTICAL CHARTS

CREATE OWN CATEGORIES & COMMENTS

ANALYZE PATENT AND NON PATENT

REPORTS AND DASHBOARDS

- Find Family Patents
- Download pdf
- Search Similar Patents
* Limited to top 100 results
SEARCH FOR FREE

Full text patents:
Australia, Indonesia, Israel,
Turkey
Retranslation of:
German, Korean, Japanese
patents
National phases BR, Malaysia,
Singapore, Philippines
Legal status :
US PAIR, Patent Trial and
Appeal Board (PTAB), Inter
Partes Review Proceedings
(IPR), Orange Book
Designs Patent search
50+ authorities searchable
Search Related enhancements :
Optimized search for non experts
Tiered indexes, Booleans &
proximities
Faster processing
Automated semantic search
Search results sorted by
relevancy
Exports: New simplified menu
(XLSX first, then other formats)
ROADMAP FOR ORBIT

IP CHALLENGES
AND
OPPORTUNITIES
FOR INDIAN PHARMA GENERICS
sandeepm@scienceinfoware.com
+91 8953745897
Questel’s Partner in India
Q & A
Contact Us its Free to Test

IP CHALLENGES AND Opportunities for Indian Pharma GENERICS

More Related Content

Similar to IP CHALLENGES AND Opportunities for Indian Pharma GENERICS

Recently uploaded

IP CHALLENGES AND Opportunities for Indian Pharma GENERICS